Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Organon & Co. stock logo
OGN
Organon & Co.
$13.78
-0.1%		$13.70
$5.69
▼
$13.80
$3.62B1.552.14 million shs2.09 million shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$36.39
+44.4%		$25.37
$18.80
▼
$36.46
$1.00B0.25565,814 shs28.90 million shs
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
$7.63
+7.3%		$5.95
$4.51
▼
$69.00
$3.52B1.18133,345 shs223,693 shs
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$72.22
-1.9%		$74.21
$53.89
▼
$91.53
$3.23B0.44735,371 shs555,509 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Organon & Co. stock logo
OGN
Organon & Co.
+0.01%+0.37%+0.08%+1.93%+34.40%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
+44.40%+45.50%+40.66%+42.82%+55.45%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
+7.31%+20.54%+11.88%+29.76%-60.67%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-1.89%-4.29%-17.20%+24.22%+3.54%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Organon & Co. stock logo
OGN
Organon & Co.
$13.78
-0.1%		$13.70
$5.69
▼
$13.80
$3.62B1.552.14 million shs2.09 million shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$36.39
+44.4%		$25.37
$18.80
▼
$36.46
$1.00B0.25565,814 shs28.90 million shs
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
$7.63
+7.3%		$5.95
$4.51
▼
$69.00
$3.52B1.18133,345 shs223,693 shs
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$72.22
-1.9%		$74.21
$53.89
▼
$91.53
$3.23B0.44735,371 shs555,509 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Organon & Co. stock logo
OGN
Organon & Co.
+0.01%+0.37%+0.08%+1.93%+34.40%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
+44.40%+45.50%+40.66%+42.82%+55.45%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
+7.31%+20.54%+11.88%+29.76%-60.67%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-1.89%-4.29%-17.20%+24.22%+3.54%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Organon & Co. stock logo
OGN
Organon & Co.
1.71
Reduce$11.40-17.25% Downside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.00
Hold$31.44-13.59% Downside
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
1.00
SellN/AN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
2.70
Moderate Buy$100.8639.65% Upside

Current Analyst Ratings Breakdown

Latest PCRX, OGN, RGC, and TARS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$38.00 ➝ $36.50
10/8/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderweight ➝ Neutral$36.50
10/8/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$36.00
10/8/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
10/7/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$30.00 ➝ $31.00
10/6/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
10/5/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
9/24/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$116.00
9/24/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$116.00
9/23/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$32.00
9/21/2026
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Organon & Co. stock logo
OGN
Organon & Co.
$6.22B0.58$5.79 per share2.38$2.89 per share4.77
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$746.16M1.94$5.57 per share6.53$16.11 per share2.26
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/AN/AN/AN/A$0.01 per shareN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$451.36M7.02N/AN/A$8.09 per share8.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Organon & Co. stock logo
OGN
Organon & Co.
$187M$0.7717.894.001.283.41%88.97%6.03%11/9/2026 (Estimated)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$7.03M$0.35103.9715.42N/A1.96%9.68%5.30%11/5/2026 (Estimated)
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
-$3.58MN/AN/AN/AN/AN/AN/AN/AN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$66.42M-$1.09N/A120.37N/A-7.67%-13.53%-8.12%11/3/2026 (Estimated)

Latest PCRX, OGN, RGC, and TARS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.7310N/AN/AN/A$182.86 millionN/A
11/3/2026Q3 2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$1.49N/AN/AN/A$182.74 millionN/A
10/7/2026Q4 2026
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/A-$0.0060N/A-$0.0060N/AN/A
8/6/2026Q2 2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$0.1918-$0.43-$0.2382-$0.43$169.65 million$173.91 million
8/4/2026Q2 2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.6460$0.73+$0.0840$0.12$191.06 million$192.40 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.58%N/A10.39%N/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
$0.8811.53%N/AN/AN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
N/AN/AN/AN/AN/A

Latest PCRX, OGN, RGC, and TARS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/31/2026
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.58%8/14/20268/14/20269/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Organon & Co. stock logo
OGN
Organon & Co.
8.43
1.95
1.44
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.54
5.04
3.94
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/AN/AN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
0.21
3.20
3.17

Institutional Ownership

CompanyInstitutional Ownership
Organon & Co. stock logo
OGN
Organon & Co.
77.43%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
99.73%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
0.13%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
90.01%

Insider Ownership

CompanyInsider Ownership
Organon & Co. stock logo
OGN
Organon & Co.
1.62%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
6.40%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
2.00%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
9.64%
CompanyEmployeesShares OutstandingFree FloatOptionable
Organon & Co. stock logo
OGN
Organon & Co.
10,000262.61 million258.36 millionNot Optionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
82939.86 million37.31 millionOptionable
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
10494.49 million484.60 millionN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
37043.88 million39.65 millionOptionable

Recent News About These Companies

Tarsus Pharmaceuticals (NASDAQ:TARS) Cut to Strong Sell at Zacks Research
October 8 at 6:06 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31099310
Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Moved Down to Strong Sell by Zacks Research
October 8 at 6:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-tarsus-pharmaceuticals-nasdaq-tars-stock-moved-down-to-strong-sell-by-zacks-research-2026-10-08/
Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options
October 6 at 8:55 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4952200-tarsus-pharmaceuticals-xdemvy-now-pays-the-bills-and-the-retina-deals-work-like-options
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Now Rated "Moderate Buy" by Wall Street Brokerages
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085589
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Now Rated "Moderate Buy" by Wall Street Analysts
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-tarsus-pharmaceuticals-inc-nasdaq-tars-stock-now-rated-moderate-buy-by-wall-street-analysts-2026-10-05/
Head-To-Head Survey: Tarsus Pharmaceuticals (NASDAQ:TARS) & Astrazeneca (NYSE:AZN)
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31084148
Tarsus to Present 11 Abstracts at Anaheim Eye Meeting
September 29, 2026  |  ocbj.comO
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry ...
September 29, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/tarsus-plans-to-present-11-abstracts-highlighting-new-insights-in-demodex-blepharitis-ocular-rosacea-and-the-real-world-impact-of-xdemvy-at-the-american-academy-of-optometry-2026-annual-meeting-1036581332
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370836/0/en/tarsus-plans-to-present-11-abstracts-highlighting-new-insights-in-demodex-blepharitis-ocular-rosacea-and-the-real-world-impact-of-xdemvy-at-the-american-academy-of-optometry-2026-a.html
Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to "Strong-Buy" at The Goldman Sachs Group
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-tarsus-pharmaceuticals-nasdaq-tars-upgraded-to-strong-buy-at-the-goldman-sachs-group-2026-09-26/
Tarsus Pharmaceuticals (TARS) Receives a Buy from Goldman Sachs
September 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TARS/pressreleases/4794598/tarsus-pharmaceuticals-tars-receives-a-buy-from-goldman-sachs/
Bank of America Corp DE Acquires New Stake in Tarsus Pharmaceuticals, Inc. $TARS
September 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-acquires-new-stake-in-tarsus-pharmaceuticals-inc-tars-2026-09-20/
Tarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC Filing
September 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/tarsus-pharmaceuticals-insider-sold-shares-203447683.html
Pyott David E I Executes Options in Tarsus Pharmaceuticals, Retains 9,575 Shares
September 18, 2026  |  kalkinemedia.comK
Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded by Barclays to Strong-Buy Rating
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-tarsus-pharmaceuticals-nasdaq-tars-upgraded-by-barclays-to-strong-buy-rating-2026-09-18/
William Phd Link Sells 12,500 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-william-phd-link-sells-12500-shares-of-tarsus-pharmaceuticals-nasdaq-tars-stock-2026-09-17/
Hsbc Holdings PLC Grows Stake in Tarsus Pharmaceuticals, Inc. $TARS
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-grows-stake-in-tarsus-pharmaceuticals-inc-tars-2026-09-12/
Wellington Management Group LLP Purchases 24,117 Shares of Tarsus Pharmaceuticals, Inc. $TARS
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-purchases-24117-shares-of-tarsus-pharmaceuticals-inc-tars-2026-09-11/
Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $905,600.00 in Stock
September 10, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-tars-insider-buying-and-selling-2026-09-10/
Squarepoint Ops LLC Buys 54,791 Shares of Tarsus Pharmaceuticals, Inc. $TARS
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-buys-54791-shares-of-tarsus-pharmaceuticals-inc-tars-2026-09-10/
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Moderate Buy" from Analysts
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-tarsus-pharmaceuticals-inc-nasdaq-tars-receives-average-rating-of-moderate-buy-from-analysts-2026-09-10/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$13.78 -0.01 (-0.10%)
Closing price 10/8/2026 03:59 PM Eastern
Extended Trading
$13.78 0.00 (-0.01%)
As of 08:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$36.39 +11.19 (+44.40%)
Closing price 10/8/2026 04:00 PM Eastern
Extended Trading
$36.37 -0.02 (-0.07%)
As of 08:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Regencell Bioscience stock logo

Regencell Bioscience NASDAQ:RGC

$7.63 +0.52 (+7.31%)
Closing price 10/8/2026 04:00 PM Eastern
Extended Trading
$7.67 +0.04 (+0.52%)
As of 08:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Tarsus Pharmaceuticals stock logo

Tarsus Pharmaceuticals NASDAQ:TARS

$72.22 -1.39 (-1.89%)
Closing price 10/8/2026 04:00 PM Eastern
Extended Trading
$72.25 +0.03 (+0.04%)
As of 08:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas